Published January 15, 2025 · Updated October 9, 2026
Semaglutide Real-World Results: Studies and Their Limits
What happens outside a clinical trial? Published observational studies offer useful context, provided their measured results stay attached to their methods and limitations.
Editorial disclosure: Written by Trimi Editorial Team. Trimi offers care that may include compounded medication. This article explains published research; it does not report Trimi outcomes or patient testimonials. Sources checked October 9, 2026. This update does not represent a new clinical review.
What do real-world semaglutide studies tell us?
They describe outcomes in selected groups receiving care outside randomized trials. The two reports below measured weight changes at defined follow-up points. Their findings do not predict an individual's result or establish outcomes for Trimi or compounded preparations.
Two published studies, with their denominators
| Publication | Design and sample | Measured weight change | Interpretation limit |
|---|---|---|---|
| Ghusn and colleagues, 2022 | Retrospective weight-management referral-center cohort. Analysis included 175 adults at three months and 102 at six months. | Mean weight reduction: 5.9% at three months; 10.9% at six months. | The six-month group is smaller. These figures do not describe all people who initially received a prescription. |
| SCOPE, 2024 | Retrospective U.S. records-and-claims study of 343 adults who reached the studied Wegovy 2.4 mg maintenance dose. | Mean weight reduction: 10.0% at six months. | Required baseline and follow-up measurements and dose escalation. The findings may not represent people who stop earlier or lack follow-up. |
The Ghusn study examined treatment with once-weekly semaglutide at 1.7 or 2.4 mg. It was observational, with no randomized placebo comparison. Its sample and follow-up limit generalization.
The SCOPE report used linked clinical records and pharmacy claims. Novo Nordisk funded the study, and several authors were employees. Its dose is a study detail, not an instruction to start or change medication.
How to assess a result claim
- Find the original publication. A percentage without a named study, population and follow-up period is difficult to evaluate.
- Check who remained in the analysis. Results among people with follow-up measurements can differ from results among everyone who started.
- Check the product and setting. A finding about a studied medication does not establish effectiveness for a different preparation or program.
- Look for funding and conflicts. These disclosures help readers assess the research alongside its methods.
These are examples of published observational evidence, not a systematic review or a complete account of all semaglutide research. For the distinction between measured trial endpoints and monthly predictions, see our guide to interpreting semaglutide results.
What this evidence does not establish
Neither report measures Trimi patient outcomes or establishes results for compounded semaglutide. FDA explains that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing.
This article cannot determine personal eligibility, predict weight change or select a dose. Discuss response, side effects and follow-up with your licensed provider. Read Trimi's important safety information for treatment risks and disclosures.
Frequently asked questions
Are real-world results the same as personal success stories?
No. A research report identifies its sample, methods and follow-up. A personal account describes one person's experience and cannot establish what another person will experience. This article reports published studies and does not present patient testimonials.
Do these studies measure Trimi or compounded semaglutide results?
No. Neither study reports Trimi patient outcomes or establishes the effectiveness of a compounded preparation. Compounded drugs are not FDA-approved; FDA does not evaluate their safety, effectiveness or quality before marketing.
Can a study average predict my monthly weight loss?
No. An average at a particular follow-up visit is not a personal forecast or a month-by-month schedule. The population, product, follow-up and missing observations matter. Discuss your own response and treatment decisions with your licensed provider.